New Information

  • Home
  • >
  • New Information
  • >
  • In the field of cosmetic medicine, the world’s first tissue augmentation (breast augmentation) with adipose tissue-derived stem cells and the Celution System was performed

In the field of cosmetic medicine, the world’s first tissue augmentation (breast augmentation) with adipose tissue-derived stem cells and the Celution System was performed

  • The world’s first breast augmentation with the use of the Celution System
  • Fully automated accurate procedure for extraction of stem cells to solve problems associated with conventional breast augmentation
  • Application of regenerative medicine technology for the establishment of anti-aging medicine on the basis of the patient’s own tissue and potential for self-renewal

Tatsuro Kamakura, the general director of Cosmetic Surgery Seishin, established the Seishin Regenerative Medicine at the Cosmetic Surgery Seishin Tokyo Clinic and performed the world’s first breast augmentation by transplantation of adipose tissue-derived stem cells with the use of the CelutionTM System (a medical device for accurate extraction of stem cells from adipose tissue) in the field of cosmetic medicine at the center on Tuesday, November 6, 2007.

In cooperation with the American biotechnology venture Cytori Therapeutics, Inc., Seishin Regenerative Medicine will enroll 20 women in a joint clinical study of tissue augmentation with adipose tissue-derived stem cells harvested with the Celution System (Cytori Therapeutics, Inc.).

Breast augmentation by transplantation of adipose tissue-derived stem cells is a technology that solves the problems associated with conventional breast augmentation. Common procedures for fat injection have a graft survival of about 30% to 50% after absorption of the majority of injected fat into the body and may be associated with calcification, lump formation, and fat necrosis. In contrast, transplantation of adipose tissue-derived stem cells is expected to allow prolonged retention of transplanted fat with a graft survival of about 70% to 80%. In addition, the use of the Celution System allows extraction of stem cells with more consistent purification of the stem cell concentrate resulting in greater purity and higher quality in a shorter time than manual extraction of stem cells.

After the introduction of the technology, Seishin Regenerative Medicine at Cosmetic Surgery Seishin expanded the system for application and widespread use of the technology in breast reconstruction and cosmetic medicine (breast augmentation) in cooperation with a group led by Dr. Keizo Sugimachi, professor emeritus at Kyushu University and a pioneer in Celution System-based transplantation of adipose tissue-derived stem cells for breast reconstruction in patients with breast cancer. Our efforts come from an increase in the number of patients with breast cancer and resulting increase in breast conserving surgeries in Japan. For women, breast deformation is highly stressful and associated with emotional distress. To help patients relieve the emotional distress of a mastectomy for breast cancer and experience the joy of living is consistent with the treatment policy of Cosmetic Surgery Seishin, that is, to provide cosmetic medicine for improvement in the QOL. Through clinical application of regenerative medicine technologies, primarily technology for transplantation of adipose tissue-derived stem cells, we work to establish anti-aging medicine on the basis of autologous tissue and self-healing potential.

Stem cells
Stem cells have the ability to differentiate into specific cells and retain the ability to reproduce and regenerate in an undifferentiated state for a long time. Embryonic stem cells (ES cells) are collected from an embryo in the early stage of development from fertilization of an egg to formation of a fetus and pre-differentiated somatic stem cells (adult stem cells) are collected from human tissue. Embryonic stem cells are characterized by their ability to become any type of cell but are associated with ethical problems. Adult stem cells are original cells capable of differentiating into a specific type of cell to form tissue and include bone marrow stem cells, hematopoietic stem cells, and mesenchymal stem cells. Adult stem cells are much less likely to induce rejection than ES cells collected from another person’s fertilized egg.
Adipose tissue-derived stem cells
These cells are a type of adult stem cell abundant in the subcutaneous adipose tissue that were found in 2001 by Dr. Marc Hedrick (then associate professor at UCLA), the founder of Cytori Therapeutics, Inc. This type of cell has the following abilities:
(1) To differentiate into a variety of cells such as adipocytes, osteocytes, chondrocytes, skeletal muscle cells, cardiac myocytes, and nerve cells.
(2) To differentiate into vascular endothelial cells to help blood vessel formation.
(3) To secret substances (such as VEGF) to induce the formation of new blood vessels.
(4) To differentiate into adipocytes for replacement when preexisting adipose tissue dies a natural death. Adipose tissue-derived stem cells are a useful cell source because of their abundance in the tissues and utility for treatment without culture.
Celution System
The system developed by Cytori Therapeutics is a high-performance system for extraction of adipose tissue-derived stem cells with the following advantages over conventional manual extraction of stem cells:
(1) More consistent volume of stem cells extracted
(2) Shorter time needed for extraction
(3) Better conditions of stem cells
(4) Minimal risk of exposure to exogenous infectious agents
(5) Reduction in labor costs
(6) Easier procedures for extraction
The system has been proven safe as evidenced by certification of ISO 10993, CE mark, and FDA approval. (In Japan, the Ministry of Health, Labour and Welfare accepted notification of the system as a medical device for analysis and testing of stem cells in October 2007.)
Cytori Therapeutics, Inc.
US Cytori Therapeutics is a global leader in the development of devices for regenerative medicine and has developed the CelutionTM System. Projects for practical application of the Celution System in breast reconstruction and treatment of cardiovascular disease and other disorders are now ongoing primarily in Europe and the United States.
Website address: http://www.cytoritx.com

■For more information

TEL:03‐5770-5292
Cosmetic Surgery Seishin Website
https://www.biyougeka.com
Seishin Regenerative Medicine Website
http://www.saisei-iryou.com
page top